Surge in out-licensing deals drive China’s international pharma collaborations
China’s out-licensing deals have significantly increased over the last five years, showcasing the country as a source of innovative drugs. The licensing agreements provide global recognition as well as validation for China’s advancements in drug development.
With China-origin innovations becoming must-watch opportunities for global pharma, collaborations with the US and EU are reaching record scale and value, says pharma analytics company GlobalData.
GlobalData’s latest report, “China’s Licensing Trends Shaping Global Drug Development”, reveals that the drug licensing boom in China means that local biotech companies are becoming recognized for the advancements they are making in First in Class (FIC) innovation. Since 2020, several out-licensing deals from China to the US and EU have been conducted across various therapy areas, but deals remain focused on oncology, with a growing interest in immunology and metabolic disorders.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze